Entyvio (Vedolizumab)
Sponsors
National Institute of Allergy and Infectious Diseases (NIAID), Hospitales Universitarios Virgen del Rocío
Conditions
HIVHIV Infections
Phase 1
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption
CompletedNCT02788175
Start: 2016-05-28End: 2019-03-04Updated: 2020-02-24
Vedolizumab Treatment in HIV-Infected Subjects Without Previous Antiretroviral Therapy
NCT03577782
Start: 2018-09-30End: 2020-05-31Target: 12Updated: 2018-07-05